Psyence Biomedical (PBM) said Monday it received a Nasdaq notification that the firm has regained compliance with all applicable Nasdaq listing requirements, including minimum market value and stockholders' equity requirement.
"With Nasdaq compliance, a debt free balance sheet and a cash position of $5.6 million, the company is well positioned to execute its business plan and clinical trial, for which patient screening has commenced," Psyence said.
Price: 2.37, Change: -0.81, Percent Change: -25.47
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。